Published in Am J Respir Crit Care Med on March 29, 2012
Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood (2014) 1.20
Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost (2013) 1.10
Endothelial protein C receptor function in murine and human breast cancer development. PLoS One (2013) 1.05
Tissue factor and cancer. Thromb Res (2012) 0.95
Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor. Cancer Res (2013) 0.91
Update in lung cancer and mesothelioma 2012. Am J Respir Crit Care Med (2013) 0.87
New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci (2015) 0.86
Influence of endothelial cell protein C receptor on breast cancer development. J Thromb Haemost (2013) 0.80
Role of the protein C receptor in cancer progression. Thromb Res (2014) 0.79
EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth. J Hematol Oncol (2017) 0.75
Endothelial protein C receptor-associated invasiveness of rheumatoid synovial fibroblasts is likely driven by group V secretory phospholipase A2. Arthritis Res Ther (2014) 0.75
Targeting clotting proteins in cancer therapy - progress and challenges. Thromb Res (2016) 0.75
AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular Disease. Pharm Regul Aff (2014) 0.75
Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model. Sci Rep (2016) 0.75
Progress in the research on the mechanism of bone metastasis in lung cancer. Mol Clin Oncol (2016) 0.75
Lung cancer: new therapeutic targets, new definitions. Am J Respir Crit Care Med (2012) 0.75
Endothelial protein C receptor polymorphisms and risk of sepsis in a Chinese population. J Int Med Res (2017) 0.75
Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. J Pathol Clin Res (2017) 0.75
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol (2007) 8.24
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
PSICQUIC and PSISCORE: accessing and scoring molecular interactions. Nat Methods (2011) 5.01
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Bioinformatics training: a review of challenges, actions and support requirements. Brief Bioinform (2010) 4.02
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 3.02
APID: Agile Protein Interaction DataAnalyzer. Nucleic Acids Res (2006) 2.91
microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res (2009) 2.80
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Bioinformatics Training Network (BTN): a community resource for bioinformatics trainers. Brief Bioinform (2011) 2.79
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol (2007) 2.46
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res (2005) 2.17
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res (2010) 2.14
Retracted Aberrant methylation of Reprimo in human malignancies. Int J Cancer (2005) 2.13
miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res (2009) 2.11
Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res (2009) 2.06
A Semantic Web management model for integrative biomedical informatics. PLoS One (2008) 2.02
Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res (2005) 2.01
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One (2009) 1.94
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res (2005) 1.94
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov (2013) 1.85
Ten simple rules for developing a short bioinformatics training course. PLoS Comput Biol (2011) 1.84
The 90S preribosome is a multimodular structure that is assembled through a hierarchical mechanism. Mol Cell Biol (2007) 1.82
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol (2007) 1.79
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One (2008) 1.72
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One (2010) 1.69
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol (2005) 1.69
Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension (2009) 1.63
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res (2009) 1.61
Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol (2003) 1.60
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res (2011) 1.59
BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol (2003) 1.59
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove. Blood (2011) 1.57
Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res (2013) 1.57
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A (2009) 1.56
Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med (2015) 1.55
Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res (2007) 1.54
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
GATExplorer: genomic and transcriptomic explorer; mapping expression probes to gene loci, transcripts, exons and ncRNAs. BMC Bioinformatics (2010) 1.52
SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. Genome Biol (2008) 1.52
Gap junctional communication modulates gene transcription by altering the recruitment of Sp1 and Sp3 to connexin-response elements in osteoblast promoters. J Biol Chem (2003) 1.50
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene (2004) 1.49
Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature. Blood (2013) 1.49
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol (2015) 1.48
A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol (2013) 1.47
Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. Genome Biol (2013) 1.47
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res (2013) 1.46
Best practices in bioinformatics training for life scientists. Brief Bioinform (2013) 1.45
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer (2006) 1.45
Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila) (2008) 1.44
Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res (2010) 1.44
Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol (2008) 1.44
GARBAN: genomic analysis and rapid biological annotation of cDNA microarray and proteomic data. Bioinformatics (2003) 1.43
Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients. Diabetologia (2013) 1.43
Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg (2011) 1.41
A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol (2014) 1.40
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One (2009) 1.39
A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res (2007) 1.39
Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res (2012) 1.39
[Early detection of lung cancer: the right time]. Med Clin (Barc) (2002) 1.39
ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo. Gene (2013) 1.38
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol (2009) 1.34
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res (2011) 1.33
Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol (2003) 1.33
Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog (2004) 1.32
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res (2012) 1.32
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol (2006) 1.31
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol (2012) 1.30
Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res (2004) 1.29
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem (2006) 1.29
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol (2012) 1.28
Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res (2008) 1.28
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res (2007) 1.25
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov (2013) 1.25
Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.24
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res (2009) 1.24
Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res (2004) 1.24